Vectus Biosystems Limited (VBS) is focused on developing treatments for fibrosis and high blood pressure, targeting major fibrotic diseases including heart, kidney, and liver conditions. In addition to its therapeutic developments, the company has created technology designed to enhance the speed and accuracy of measuring DNA and RNA levels in laboratory samples. This dual approach aims to address both significant health challenges and improve diagnostic capabilities.